Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 17/20 | 1.00 |
| ▸ | CSNK1E | P49674 | 12/20 | 0.98 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.98 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.98 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.98 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.98 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.98 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.98 |
| ▸ | LCK | P06239 | 1/20 | 0.98 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.98 |
| ▸ | GSK3B | P49841 | 1/20 | 0.98 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.98 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.98 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.98 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.53 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | FRK | P42685 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9933154 | 0.90 | CSNK1D (0.81) | CSNK1DCSNK1EMAPK14MAP4K4MAPK9 | |
| SCHEMBL9932821 | 0.89 | CSNK1D (0.80) | CSNK1DCSNK1EMAPK14MAP4K4MAPK9 | |
| SCHEMBL9933303 | 0.87 | CSNK1D (0.77) | CSNK1DCSNK1EMAPK14MAP4K4MAPK9 | |
| SCHEMBL9933197 | 0.84 | CSNK1D (0.73) | CSNK1DCSNK1EMAPK14MAP4K4MAPK9 | |
| SCHEMBL18575626 | 0.84 | CSNK1D (0.73) | CSNK1DCSNK1EMAPK14MAP4K4MAPK9 | |
| SCHEMBL9933664 | 0.84 | CSNK1D (0.71) | CSNK1DCSNK1EMAPK14MAP4K4MAPK9 | |
| SCHEMBL18575627 | 0.84 | CSNK1D (0.71) | CSNK1DCSNK1EMAPK14MAP4K4MAPK9 | |
| SCHEMBL9932714 | 0.84 | CSNK1D (0.71) | CSNK1DCSNK1EMAPK14MAP4K4MAPK9 | |
| SCHEMBL9932034 | 0.84 | CSNK1D (0.71) | CSNK1DCSNK1EMAPK14MAP4K4MAPK9 | |
| SCHEMBL18575624 | 0.84 | CSNK1D (0.71) | CSNK1DCSNK1EMAPK14MAP4K4MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3181133-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | Pfizer Inc (US) | 2017-06-21 | — | — | EP | claimed |
| EP-2654750-B1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER (US) | 2017-03-08 | — | — | EP | claimed |
| EP-2654750-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | Pfizer Inc (US) | 2013-10-30 | — | — | EP | claimed |
| US-8536164-B2 | Fused pyridine compounds as casein kinase inhibitors | PFIZER INC. (US) | 2013-09-17 | — | — | US | claimed |
| WO-2012085721-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER INC. (US) | 2012-06-28 | — | — | WO | claimed |
| US-20120157440-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER INC | 2012-06-21 | — | — | US | claimed |
| US-20210177847-A1 | Compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2021-06-17 | — | — | US | disclosed |
| US-10973820-B2 | Compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2021-04-13 | — | — | US | disclosed |
| WO-2020249717-A1 | CASEIN KINASE 1 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION SUCH AS MUSCULAR DYSTROPHY AND CANCER | Facio Intellectual Property B.V. (NL) | 2020-12-17 | — | — | WO | disclosed |
| EP-3181133-B1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER (US) | 2019-07-24 | — | — | EP | disclosed |
| EP-3181133-B1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER (US) | 2019-07-24 | — | — | EP | disclosed |
| WO-2019115711-A1 | COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2019-06-20 | — | — | WO | disclosed |
| EP-3498278-A1 | COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2019-06-19 | — | — | EP | disclosed |
| US-8536164-B2 | Fused pyridine compounds as casein kinase inhibitors | PFIZER INC. (US) | 2013-09-17 | — | — | US | disclosed |
| WO-2012085721-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085721-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120157440-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER INC | 2012-06-21 | — | — | US | disclosed |
| US-20120157440-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER INC | 2012-06-21 | — | — | US | disclosed |
| US-20120157452-A1 | 1H-PYRAZOLO[3,4-B] PYRIDINE COMPOUNDS FOR INHIBITING RAF KINASE | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157440-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER INC | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157452-A1 | 1H-PYRAZOLO[3,4-B] PYRIDINE COMPOUNDS FOR INHIBITING RAF KINASE | BRAF, RAF1, ARAF | CSNK1D 332/4885CSNK1E 215/4885MAPK14 48/4885 |
| US-20210177847-A1 | Compounds for treatment of diseases related to DUX4 expression | SMN1; SMN2, UTRN, DDX21 | CSNK1D 3706/4885CSNK1E 2990/4885MAPK14 4269/4885 |
| US-10973820-B2 | Compounds for treatment of diseases related to DUX4 expression | ZFX, MTPN, UTRN | CSNK1D 2691/4885CSNK1E 2897/4885MAPK14 4441/4885 |
| US-20120157440-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | CSNK1A1, CSNK1A1L, CSNK1E | CSNK1D 10/4885CSNK1E 3/4885MAPK14 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.